Fidaxomicin Use and Clinical Outcomes for Clostridium difficile–Associated Diarrhea

BACKGROUND: Fidaxomicin has been scrutinized because of its high acquisition cost. Real-world experience is needed to determine whether fidaxomicin has value in patients with Clostridium difficile–associated diarrhea (CDAD) and certain risk factors. METHODS: In this single-center, retrospective coho...

Descripción completa

Detalles Bibliográficos
Autores principales: Eiland, Edward H., Sawyer, Adam J., Massie, Nicholas L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280276/
https://www.ncbi.nlm.nih.gov/pubmed/25574116
http://dx.doi.org/10.1097/IPC.0000000000000181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280276/
https://www.ncbi.nlm.nih.gov/pubmed/25574116
http://dx.doi.org/10.1097/IPC.0000000000000181

Ejemplares similares